Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-80
SponsorZhejiang Hospital
About this trial
This study was designed as a single-center retrospective analysis aimed at investigating whether COVID-19 infection increases the risk or burden of radiation-induced pneumonitis in breast cancer patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients with pathologically or cytologically confirmed primary breast cancer,
aged 18 years or older but younger than 80 years,
with complete and reliable medical records,
for those with COVID-19 infection, documented evidence of a positive test result.
Disqualifiers
concomitant pulmonary malignancies,
a history of prior thoracic radiotherapy,
concurrent pulmonary infections other than COVID-19 during radiotherapy,
missing key data with loss to follow-up,
Trial population
Breast cancer patients who underwent radiotherapy at the Cancer Center of Zhejiang Hospital between January 1, 2021, and June 30, 2024, were screened for eligibility.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
COVID-19
Other interventionThe COVID-19 infection situation was used as an intervention measure, and the cohort was divided into groups.
Treatment groups
200 Participants
are divided into 2 treatment groupsGroup A: Without COVID-191 intervention
Group B: With COVID-191 intervention
Trial outcomes
Primary outcomes
1
Radiation Pneumonitis Situation
The incidence rate, severity and onset time of radiation pneumonitis
Time frame
From January 2021 to June 2024Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: